Lead PALOMA-2 Author Says Results Will Boost Global Use of Palbociclib
November 28th 2016Results from the phase III PALOMA-2 study—which demonstrated a significant progression-free survival advantage with palbociclib (Ibrance) plus letrozole compared with letrozole alone in ER-positive, HER2-negative metastatic breast cancer—were recently published in The New England Journal of Medicine.
Read More
HPV-Vaccinated Patients Require Less Frequent Cervical Cancer Screening
November 17th 2016Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.
Read More
Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients
November 13th 2016Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.
Read More
More Than Half of Cervical Cancer Patients Not Receiving Recommended Treatment
November 8th 2016Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.
Read More
Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment
November 3rd 2016Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.
Read More
Novel Agents, Combinations Advance Second-Line RCC Care
October 27th 2016The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.
Read More
Topalian Discusses the Evolution of PD-1/PD-L1 Inhibitors in Cancer Care
October 24th 2016Suzanne L. Topalian, MD, discusses the development of PD-1/PD-L1 inhibitors, emerging biomarkers, and why a precision medicine approach is necessary to identify effective immunotherapy combination regimens.
Read More
Study Explores Mutation Discordance Between Primary, Metastatic Sites in CRC
October 20th 2016Mutation discordance between primary and metastatic sites in colorectal cancer may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.
Read More